A follow-up study of 25 patients with pancreatic cancer receiving gemcitabine and cisplatin and 21-h infusional 5-fluorouracil

Abstract

Objective: The purpose of this study was to assess clinical characteristics and survival of patients with advanced pancreatic cancer who were treated with gemcitabine, cisplatin, and 21-h infusional 5-fluorouracil (5-FU).

Methods: This study was a prospective, observational study at a medical center in Western Iran. The clinical and survival data from 25 patients treated with gemcitabine, cisplatin, and 21-h infusional 5-FU at our center were prospectively assessed. Patients received chemotherapy consisting of cycles of continuous infusion of 5-FU (650 mg/m²) for 21 h on Days 1, 2, 3, and 4. Gemcitabine was administered at a dose of 1 g/m² on Days 1 and 8, and cisplatin was administered at a dose of 60 mg/m² on Day 1, with granulocyte colony-stimulating factor (G-CSF) support. Each cycle was repeated every 21 days for 5-6 cycles.

Results: A total of 25 patients with an age range of 39-73 years were studied. One out of the two patients with stage Ⅱ cancer survived for more than 43 months. Four out of the 14 patients with stage Ⅱ cancer survived for more than 15 months. Seventeen patients died, and eight subjects were alive at the end of the study. The mean and median of overall survival (OS) rates for the 25 patients were 20 and 12 months, respectively. The median progression-free survival (PFS) was 6 months.

Conclusion: It seems that the triple therapy with gemcitabine, cisplatin, and infusional 5-FU afforded significant PFS and OS benefits in patients with advanced pancreatic cancer.

Keywords

pancreatic cancer / infusional 5-flurouracil / gemcitabine / cisplatin / overall survival

References

[1] Khalaf N , El-Serage HB , Abrams HR , Thrift AP . Burden of pancreatic cancer: from epidemiology to practice. Clin Gastroenterol Heptatol. 2021; 19 (5): 876- 884.

[2] Siegel RL , Miller KD , Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68 (1): 7- 30.

[3] Saad AM , Turk T , Al-Husseini MJ , Abdel-Rahman O . Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study. BMC Cancer. 2018; 18 (1): 688.

[4] Pimienta M , Edderkaoui M , Wang R , Pandol S . The potential for circulating tumor cells in pancreatic cancer management. Front Physiol. 2017; 8: 381.

[5] Wagner M , Redaelli C , Lietz M , Seiler CA , Friess H , Büchler MW . Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004; 91 (5): 586- 594.

[6] Carrato A , Falcone A , Ducreux M , et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. J Gastrointest Cancer. 2015; 46 (3): 201- 211.

[7] Conroy T , Desseigne F , Ychou M , et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364 (19): 1817- 1825.

[8] Von Hoff DD , Ervin T , Arena FP , et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369 (18): 1691- 1703.

[9] Moore MJ , Goldstein D , Hamm J , et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25 (15): 1960- 1966.

RIGHTS & PERMISSIONS

The Author(s). Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.